Theravance Biopharma (TBPH) Return on Equity (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Equity climbed to 0.0% in Q1 2026 per TBPH's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Equity peaked at 0.15% in Q3 2022 and troughed at 0.0% in Q3 2024.
• A 5-year average of 0.01% and a median of 0.0% in 2024 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2022 and 2023: Return on Equity rose 15 bps in 2022, then decreased 15 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then tumbled by 111 bps to 0.0% in 2023, then surged by 60 bps to 0.0% in 2024, then surged by 45 bps to 0.0% in 2025, then jumped by 65 bps to 0.0% in 2026.
• Business Quant data shows TBPH's Return on Equity at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.